Pfizer Exceeds Q3 Estimates, Raises COVID-19 Vaccine Sales Forecast | Photo credits: pio3 / Shutterstock.com
Nov 1 (Reuters) – U.S. pharmaceutical group Pfizer Inc on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion (2.01 billion euros) to $34 billion, driven by demand for its new bivalent vaccines.
Although the demand for coronavirus vaccines is falling in some countries, the deployment of anti-Covid reminders is underway in the United States and Europe.
“Our COVID-19 franchises will remain multi-billion dollar revenue generators for the foreseeable future,” said Albert Bourla, the group’s chief executive.
In the third quarter, Pfizer’s sales reached $22.60 billion, beating the consensus of $21.04 billion established by analysts IBES/Refinitiv.
The company also maintained its full-year sales forecast for the anti-Covid pill Paxlovid at $22 billion. (1 euro = $0.9933) (Report Manas Mishra, French version Lina Golovnya)